Celgene's Revlimid hits goal in multiple myeloma study, stock jumps
This article was originally published in Scrip
Executive Summary
Celgene said its blood cancer drug Revlimid met a study goal of treating newly diagnosed patients with multiple myeloma. Shares of the big US biotech company rose to a new record as investors saw the results as a path to higher sales for Celgene’s biggest drug.